Therapeutic Asset Ratings

6,299 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
tc011 Diffuse Large B-Cell Lymphoma	TICAROS Co., Ltd.	P1/2	CC (45)
tc011 Primary Mediastinal Large B-Cell Lymphoma	TICAROS Co., Ltd.	P1/2	CC (45)
tc-510 Malignant Mesothelioma	TCR2 Therapeutics	P1/2	CC (45)
tcc1727 Melanoma	Beijing Tide Pharmaceutical Co., Ltd	P1/2	CC (45)
tcc1727 Non-Small Cell Lung Carcinoma	Beijing Tide Pharmaceutical Co., Ltd	P1/2	CC (45)
Tc-N201 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1/2	CC (45)
Tcr Alpha Beta / Cd19+ Depleted Haploidentical Hematopoietic Progenitor Cell Graft Childhood Acute Myeloid Leukemia	Washington University School of Medicine	P1/2	CC (45)
T-Dxd Cancer	Daiichi Sankyo	P1/2	CC (45)
T-Dxd Colorectal Cancer	Iambic Therapeutics, Inc	P1/2	CC (45)
Tegavivint Hepatocellular Carcinoma	Iterion Therapeutics	P1/2	CC (45)
Tegavivint Neuroblastoma	Children's Oncology Group	P1/2	CC (45)
Tegavivint Ovarian Carcinoma	Children's Oncology Group	P1/2	CC (45)
Tegavivint Refractory Malignant Neoplasm	Children's Oncology Group	P1/2	CC (45)
Temuterkib Colorectal Cancer	The Netherlands Cancer Institute	P1/2	CC (45)
Temuterkib Colorectal Carcinoma	M.D. Anderson Cancer Center	P1/2	CC (45)
Temuterkib Rectal Cancer	M.D. Anderson Cancer Center	P1/2	CC (45)
Tgrx-814 Adult Acute Lymphoblastic Leukemia	Shenzhen TargetRx Co., Ltd.	P1/2	CC (45)
Tgrx-814 Non-Hodgkin Lymphoma	Shenzhen TargetRx Co., Ltd.	P1/2	CC (45)
Tgx-007 Glioblastoma	Trogenix ltd	P1/2	CC (45)
th9619 Head And Neck Squamous Cell Carcinoma	One-carbon Therapeutics AB	P1/2	CC (45)
Theo-260 Ovarian Cancer	Theolytics Limited	P1/2	CC (45)
Therapeutic 4Scar19 Cells B-Cell Neoplasm	Shenzhen Geno-Immune Medical Institute	P1/2	CC (45)
TIL Brain Cancer	Essen Biotech	P1/2	CC (45)
TIL Rectal Cancer	Essen Biotech	P1/2	CC (45)
TIL Neoplasm	Fujian Cancer Hospital	P1/2	CC (45)

Showing 3851 to 3875 of 6,299 assets

PreviousPage 155 of 252Next